A Dose-Response Controlled Trial of Bevifibatide for Acute Ischemic Stroke

Bevifibatide is a derivative similar to Eptifibatide, differing by only one amino acid:in the position where Eptifibatide contains high arginine, it is replaced by arginine toform Bevifibatide. Bevifibatide can specifically bind to the GPIIb/IIIa receptor,inhibiting platelet aggregation or adhesion. It also inhibits the integrin receptor αvβ3,thereby suppressing the growth of vascular smooth muscle and playing an important role inpreventing arterial re‐occlusion. Bevifibatide is a post‐marketing product indicated forunstable angina, non‐Q wave myocardial infarction, non‐ST segment elevation myocardialinfarction, and anti‐thrombotic therapy during and around percutaneous coronaryintervention. Its clinical formulation is an injectable solution for intravenousadministration. When Bevifibatide is used in combination with clinical baselinemedications, it has a synergistic effect on anti‐platelet aggregation. Early oraladministration of aspirin and clopidogrel can achieve a rapid synergistic effect onanti‐platelet aggregation.Currently, there are no clinical trials assessing the relationship between the dosage ofBevifibatide and its efficacy in treating acute ischemic stroke. We conduct asingle‐center, randomized, double‐blind, dose‐response controlled clinical trial topreliminarily evaluate and compare the effectiveness of conventional dosage and lowmaintenance dosage of Bevifibatide citrate injection in improving neurological outcomesat 90 days and the incidence of symptomatic intracranial hemorrhage in patients sufferingfrom acute ischemic stroke without large or medium‐sized vessel occlusion, therebydetermining a relatively safe dosage while maintaining the effectiveness of themedication, and providing a dosage basis for conducting large‐sample randomizedcontrolled trials.